Rapidscan Pharma claims Rapiscan is a non-weight based, infusion pump-free pharmacological stress agent available in the UK.
Unlike older agents, Rapiscan requires no dose adjustment for varying body weight and is administered as a 10 second injection, which cuts the need for an infusion pump, extension line and infusion line set-up.
Regadenoson was discovered and developed by CV Therapeutics and was approved by the US Food and Drug Administration in April 2008, where it is sold by Astellas Pharma US.
Gilead Sciences acquired CV Therapeutics in 2009.
EU Commission Licence was granted by the European Medicine Agency in September 2010.
In the UK and Germany, Rapiscan (regadensoson) is distributed by GE Healthcare.